 Assessing diabetes severity is important and could help identify people in need for targeted therapies and benchmark healthcare services.
Introduction
Diabetes mellitus is a long-term metabolic condition associated with an increased risk of morbidity and premature mortality, with type 2 diabetes forming over 90% of all cases of diabetes [1] . Globally, the management of people with non-communicable long term conditions (such as diabetes and heart disease) forms one of the greatest challenges facing healthcare systems [2] . The prevalence of diabetes has risen rapidly [3, 4] contributing to an estimated 1.6 million deaths worldwide in 2016 [5] . The World Health Organization (WHO) estimates that diabetes was the seventh leading cause of death in 2016 [5] . The 'severity' of clinical conditions can be conceptualised as a progression of the underlying disease process, where increasing severity and the associated complications lead to increased treatment complexity and greater impact on clinical resources [6] . Assessing disease severity in diabetes is important because it: i) enables identification of people in greater need for more targeted and intensive therapies for risk stratification and to reduce adverse outcomes; ii) could optimise the allocation of healthcare resources towards those at greatest risk of harm; and iii) could provide a useful means of benchmarking clinical services. Currently, clinicians mainly use glycated haemoglobin (HbA1c) levels as a proxy of diabetes severity and for management recommendations. However, using HbA1c levels is limited being a unidimensional measure, reliance is mainly on last recorded test, the quality of recorded data in primary care is questionable despite recent improvements. In addition, given the multi-organ involvement in diabetes, a more inclusive proxy for diabetes severity is recommended and needed.
The electronic recording of clinical records has developed substantially since its initiation in the 1980s [7] and becoming an important component underpinning clinical decision making and systematic care quality improvement [8] . Longitudinal electronic health records (EHRs) also enable the study of population health dynamics and form a powerful tool to improve the quality and value of health care services [9] . EHRs represent real-world data, and are expected to meet minimum standards for data quality [10, 11] , and are inclusive of all patient groups encountered in routine clinical practice that are often excluded in clinical trials (pregnant women, children, the elderly, and people with multiple illnesses). Despite the widespread use of EHRs in healthcare systems across the world, they are not routinely used in quantifying the severity of long-term conditions such as diabetes. Using such rich medical data to develop severity measures for diabetes could represent a practical aid for practitioners, supporting clinical management and service-planning.
Generic severity tools, such as the Charlson Comorbidity Index (CCI) [12] or the Duke Severity of Illness (DUSOI) checklist [13] are available but the applicability of such global measures of comorbid burden and their relevance specifically to people with diabetes, is unclear. Other tools have been developed that incorporate diabetes, such as the QRISK2 risk assessment tool (recommended to assess cardiovascular disease (CVD) risk in people with type 2 diabetes) [14] but this also provides limited information on diabetes severity. Furthermore, existing cardiovascular risk scores perform poorly in people with type 2 diabetes. [15] Considering the increasing disease prevalence, bespoke tools to assess diabetes severity need to be developed.
There has been no comprehensive review on the use of health records to develop a diabetes-specific severity indices and their predictive values. In this paper we present a critical review of studies that have quantified the severity of type 2 diabetes using medical data and EHRs. In our review we aimed to: i) describe the design, included domains and measured clinical outcomes of identified type 2 diabetes severity measures; ii) synthesize the association between type 2 diabetes severity levels and health-related outcomes; and iii) identify the likely best-performing severity measure(s) or with potentials of influencing clinical interventions based on the importance and clinical coherence of included severity domains, utility for primary care, and prospective association with clinical outcomes.
Methods
A protocol for this review is registered in the international prospective register of systematic reviews (PROSPERO registration number: CRD42018103147). Our review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and MOOSE guidelines [16, 17] .
Data Sources and Searches
We conducted our search of three main databases from inception to include all available studies. We searched MEDLINE (from 1964 to June Week 3, 2018) and
Embase (from 1974 to June 20, 2018) using the OVID platform, and PubMed (from inception to June 20, 2018) . The searches consisted of four core blocks of terms in relation to 'diabetes', 'severity', 'grading' and 'stratification'. A combination of keywords and MeSH terms were used with appropriate Boolean operators. The detailed search strings are listed in Appendix S1. The search strategy was finalised by checking for coherence with prior scoping review results from Web of Science and PubMed.
Study Selection
Identified papers were considered eligible if they developed a system for grading the severity of type 2 diabetes using a model or algorithm utilising medical record data. In the first step, one reviewer (S.Z.) screened the references by titles and abstracts to assess eligibility and exclude irrelevant papers. The remaining potentially eligible papers were then assessed independently by titles and abstracts by two reviewers (E.K. and S.Z.) and any discrepancies were resolved by discussion. Cohen's kappa was used to measure the agreement between both assessments. Full-text review of eligible papers were screened by S.Z. A batch of the eligible papers was reviewed in full text by a second reviewer (E.K.). The two reviewers agreed on all decisions regarding inclusions and exclusions and therefore just one reviewer continued to screen full-text papers.
Data Extraction and Quality Assessment
One researcher (S.Z.) extracted relevant information from the final full-text papers in pre-designed MS Excel form, including: author(s), year of the study, country, and study population demographics (age, gender, duration of diabetes), study design, sample size, variables included to assess severity, design of severity algorithm, the process of severity score assignment and score calculation, the outcome(s) associated with graded severity (if any), the measure validation (if conducted), and a summary of the main findings. Studies to be critically appraised using an appropriate quality assessment tool, based on the type of the identified studies.
Data synthesis and Analysis
The primary aim of this review was to identify and describe existing severity measures used to assess the severity of type 2 diabetes. The data were narratively synthesised and interpreted by:
1. Describing the characteristics and critically evaluating the design of measures used to define the severity of type 2 diabetes and identify the included severity domains (predictors that are relevant to the degree of progression of type 2 diabetes) and reported outcomes.
2. Synthesising the association between diabetes severity levels and healthrelated outcomes.
3. Identifying the best-performing measure(s) based on performance, the breadth of included severity domains and their relevance to primary care.
Results
Our search resulted in 6,798 studies, of which 3,555 duplicates were removed. The initial title (and abstract as needed) screening stage of the non-duplicate references resulted in the exclusion of 2,893 irrelevant articles. From the remaining 350 papers, which were screened independently by two authors (Cohen's Kappa rater agreement = 0.95), a further 332 papers were excluded and 18 articles were eligible for full-text review. Five of the 18 eligible papers were independently reviewed in full text by a second reviewer.
One study was excluded [18] after full-text review as a duplication of a previouslydeveloped diabetes severity measure (already in our review) [19] by updating International Classification of Diseases (ICD) codes from ICD-9 to ICD-10. In agreement with our eligibility criteria, we retained the paper describing the original severity measure. The remaining 17 studies were included in the review. The search and selection stages are illustrated in the PRISMA flowchart chart (Fig. 1 ). The PRISMA checklist is presented in Appendix S2 and the MOOSE checklist in Appendix S3.
No single quality assessment tool could be used to evaluate the included papers, due to their very different designs (e.g. risk prediction models, observational studies or other), since such tools include study-type-specific domains.
Characteristics of the Included Studies
Overall, a total of 18 diabetes severity measures reported in 17 studies were evaluated. The included studies assessed diabetes severity using various approaches, primarily by using either severity categories or a numerical score. Table   1 presents a summary of the main participants' characteristics for each of the 17 studies included in the analysis. Of the identified studies, published between 1994 and 2018, the majority were based in the USA [19] [20] [21] [22] [23] [24] [25] [26] while other studies originated from
China [27] , Denmark [28] , Germany [29] , Italy [30] , the Netherlands [31] , Spain [26] , Japan [32] , and Australia [33] . One study included participants from 16 countries (Australia, Austria, China, Czech Republic, Germany, Denmark, Spain, France, Hong Kong, Hungary, Italy, Japan, Korea, Poland, Russia, and the USA) [34] . No studies were identified from other countries well-known for their high availability of national administrative data, such as the UK. Ten studies were cross-sectional [19, 20, 23, 25, 28, [31] [32] [33] [34] [35] ; six were retrospective [21, 22, 24, 26, 29, 30] ; and only one reported a prospective design by assessing the relationship between longitudinal severity and clinical outcome [27] . The study populations consisted mainly of people with type 2 diabetes only (N=2,889 in 10 studies, 59%), but seven studies (41%) included participants with other forms of diabetes in addition to type 2 diabetes (mainly type 1 diabetes). These seven studies did not describe the distribution of participants by the type of diabetes, except in one study where participants with type 1 and type 2 diabetes formed 12% (N=492) and 88% (N=3,737), respectively [19] . The total population from all studies was 32,314 (including participants without diabetes for comparison), while the sample size of participants with diabetes was 15,283 (47%) and ranged in individual studies between 65 and 4,229 participants. In all, participants were aged between 30 and 90 years, of whom 0.0%-71% were women. Middle-aged and older people with type 2 diabetes [20] , veterans, and first-time heart transplant recipients with diabetes were included in some of the eligible studies [22] [23] [24] [25] .
Characteristics of Diabetes Severity Measures
Details for the severity measures design, included domains and reported outcomes of diabetes severity outcomes across studies are presented in Table 2 .
Severity Measures Design
Four different designs of diabetes severity measures were identified across the 18 included measures: i) developing a composite severity index or measure (8 measures, 44%); ii) using categories of disease severity (7 measures, 39%); iii) using a diabetes symptom checklist (1 measure, 6%); and iv) using a simple count of diabetic complications (2 measures, 11%).
i) Composite Severity Index or Measure
In these studies (8 studies across 11,138 participants), diabetes severity scores were either developed as a continuous scale or as a composite severity measure using predetermined severity domains [19, 20, [22] [23] [24] [25] [26] 32] . Severity scales were based on assigning a score (a simple count or a weighted score) to each of the defined severity indicators, and from these individual scores, an overall score was calculated. These severity measures included clinical indicators including: body mass index (BMI), glycated haemoglobin (HbA1c), diabetes duration, type and number of prescribed medications, renal function, blood pressure, and diabetes-related microvascular and macrovascular complications.
ii) Categories of Disease Severity
In studies using severity level categories (7 studies across 2,640 participants), participants were categorised as having between two to six levels of severity by predefined diabetes-related criteria [21, 27-30, 33, 35] . The categories were based on insulin use, diabetes therapy intensity, the presence of diabetes-related microvascular and macrovascular complications, glucose and HbA1c levels, diabetes duration, and history of hypoglycaemia.
iii) Simple Count of Diabetic Complications
In studies using a count of conditions (2 studies across 5,549 participants), diabetes severity was assessed based on a count of diabetes-related complications. In the first study, the severity assessment was based on a simple sum of the number of diabetic microvascular and macrovascular complications in 4,229 participants with diabetes (type 1 diabetes and type 2 diabetes) from one US geographic region [19] . In the same study, the simple count was compared to a composite diabetes severity index (as described above) in predicting the risk of hospitalisation, healthcare utilisation and mortality. The second study included 1,320 participants with diabetic macular oedema enrolled from four studies in 16 countries [34] . The simple count was based on the sum of presence or absence of five conditions (pseudophakia, diabetic neuropathy, diabetic nephropathy, peripheral vascular disorder, and proteinuria). Each participant was assigned a score between 0 (for people without any of these conditions) and 5
(people with all five conditions).
iv) Diabetes Symptoms Checklist
One study used a checklist developed to measure perceived symptom severity and assess change over time in 185 participants with type 2 diabetes [31] . The 34-item participant-derived clinical checklist categorised diabetes symptom severity into six clinical domains including: hyperglycaemic, hypoglycaemic, cardiovascular, psychological, neuropathic and ophthalmic. The sample size was however relatively small and the checklist was mainly based on participants' perception of diabetes severity.
Severity Domains
Diabetes-related complications were the most commonly used domains to assess diabetes severity, as reported in 11 (61%) of the severity measures [19, 21, 23, 25, 27, 28, [30] [31] [32] [33] [34] . Microvascular complications (diabetic neuropathy, nephropathy and retinopathy) and macrovascular events were included. Glycaemic control was the second most-commonly included domain, with levels of blood glucose and/or HbA1c used in eight (44%) severity measures [21, 22, 26-29, 32, 35] . The complexity of antidiabetic treatment domain was also used in four (22%) severity measures and was assessed as insulin use and/or the number of prescribed anti-diabetic therapies (monotherapy versus drug combinations) [20, 29, 30] . Other domains used to assess diabetes severity were diabetes duration [26, 35] ; blood pressure levels [22, 28] ; the presence of renal disease (levels of albuminuria [28] and/or serum creatinine) [19, 22, 25] ; a composite score of: quality of life indicators and counts of comorbidities and prescribed medications [20] ; demographic variables (age, gender, ethnicity, marital status) [22] ; BMI [22] ; low density lipoprotein (LDL) levels [22] ; a composite history of: cerebrovascular and/or cardiovascular disease, severe obesity, and renal failure before heart transplantation [24] .
Measured Outcomes
The measured outcomes varied form general measures of use of healthcare resources and measures of health-related outcomes. In all, the clinical outcomes most-frequently related to diabetes severity levels were the risk for hospitalisation (one study), [19] healthcare utilisation and/or costs (three studies) [21, 22, 33] , and mortality (three studies) [19, 24, 33] . Less-frequently, other outcomes assessed in relation to diabetes severity in individual studies included haematological changes [32] , physical or cognitive function [20, 23, 35] , changes in diabetes therapy after bariatric surgery [29] ;
long-term diabetes remission and selection of metabolic surgery [26] ; obesityassociated protein expression [27] ; and participant satisfaction [25] . Four studies have validated the developed severity measures using a separate dataset or by mapping them to clinical outcomes [19, 22, 26, 33] . One study used positive predictive value (PPV) to assess the developed type 2 diabetes severity measure ( Table 2 ) [30] .
Synthesising the Association between Severity Levels and Health-

Related Outcomes
The studies that assessed diabetes severity and hospitalisation found that higher severity was associated with significantly greater risk for hospitalisation [19] .
Assessing the relationship between severity of diabetes and healthcare costs and adverse events revealed that worsening diabetes was associated with higher mean monthly in-patient costs, pharmaceutical and medical costs [21, 22, 33] , and significantly increased risk for mortality [19, 33] . Severity of diabetes was also related to lower patient satisfaction with diabetes care received, cognitive dysfunction and significantly higher risks for adverse outcomes -mainly mortality [19-21, 25, 33] .
Diabetes severity levels were also associated with immunological and haematological changes [32] . Table 2 details the association between measured severity and outcomes reported in the included studies. The first of the two studies that validated the severity measures in a separate population (Spain) reported similar findings to those found from the training dataset (USA) [26] . The second study reported differences between both datasets in the association between diabetes severity and one of two examined outcomes [22] .
Clinical Performance of Diabetes Severity Measures
Among the included studies that developed a severity index, the measure reported by protein levels (that positively correlate to waist circumference, BMI and blood glucose indices)) increased with increasing type 2 diabetes severity, but significantly declined following a 12-week treatment in comparison to before treatment [27] .
Discussion
Summary of Main Findings
Main findings: This systematic review aimed to provide an overview of existing measures assessing the severity of type 2 diabetes using clinical data. Our review has
shown that there has been little development with practical applications of diabetesspecific severity measures. We found that: i) the most commonly used clinical variables for grading type 2 diabetes severity were diabetes-related complications and glycaemic control measures; ii) only a few studies considered the type or patterns of prescribed (diabetes and non-diabetes) therapies as a proxy for higher severity or We focused on the clinical rather than methodological characteristics of the included diabetes studies and severity measures. Given the widely different designs of the included studies, no consistent quality assessment tool could be applied successfully to evaluate the included papers as the tools' specific criteria are not applicable to the included heterogeneous studies.
Challenges and clinical opportunities of developing diabetes severity scores:
Our review of the literature has shown that there has been little development and few practical applications of diabetes-specific severity indices. There is therefore considerable scope to work towards advances in refining these indices as reliable and 
Limitations and Strengths of This Review
Our review is limited, firstly, by excluding studies reporting only on other forms of diabetes. Although measuring the severity of other forms, mainly type 1 diabetes, could be relevant, our focus was on adults with type 2 diabetes in adult population because this represents ~90% of all diabetes. Secondly, some of the studies were based on people with diabetes managed in specialist facilities and not in routine clinical settings, such as veterans and individuals undergoing heart transplantation.
Therefore, the findings in these selective populations are only likely to be applicable in these specific groups and may not generalise well to the wider type 2 diabetes population seen mostly in primary care. Thirdly, given the scope of this review and the heterogeneous design of included studies, we were not able to critically appraise the studies using available and recognised quality assessment tools. Our review has several strengths: firstly, to our knowledge this is the first systematic review identifying measures quantifying the severity of type 2 diabetes using medical data, mostly collected in clinical settings. Secondly, we used a broad search strategy; inclusion criteria had no restriction on year or language. Thirdly, two independent reviewers performed the second screening stage. Finally, the review was conducted and recorded in accordance to the PRISMA guidelines [16] .
Implications
Clinical Therefore, a composite score that encompasses all relevant severity domains in people with diabetes may be needed. Importantly, the recent consensus report by the ADA and the EASD included a recommendation for providing patient-centred care that takes multimorbidity into account [36] . Future clinical guidelines for management of type 2 diabetes need to provide more comprehensive recommendations that would help healthcare professionals to address the rapidly increasing prevalence of multimorbidity, a main indicator of increasing disease severity, in people with type 2 diabetes. Further research is needed as the potential for these developments is particularly high in countries where primary care EHRs or national disease registries contain comprehensive, clinician-coded data, often supported by financial incentives [37, 38] . A more inclusive severity index validated using important clinical outcomes in a large diabetes population cohort, will be welcome. Such a measure would serve as an important proxy for health status and in decision making in diabetes care.
Generalisability: Our findings may have greatest generalizability in countries that
have access to routinely-collected administrative data, as evidenced by the numerous countries in which these studies were conducted and the heterogeneity of the study populations. Unsurprisingly, the more recently developed severity measures appear to be more promising and better-founded -supported by the rapidly growing availability of clinical data and well-characterised diabetes cohorts. This and the quick evolution of rich EHRs offer an unprecedented opportunity to use these clinical data to develop comprehensive measures assessing diabetes severity and optimal impact in clinical care.
In conclusion, this systematic review highlights that the assessment of type 2 diabetes severity using routinely-collected real-world clinical and administrative data is under- 
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